Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 386.53
TGTX's Cash to Debt is ranked higher than
55% of the 830 Companies
in the Global Biotechnology industry.

( Industry Median: 56.40 vs. TGTX: 386.53 )
TGTX' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 386.53

Equity to Asset 0.91
TGTX's Equity to Asset is ranked higher than
86% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. TGTX: 0.91 )
TGTX' s 10-Year Equity to Asset Range
Min: 0.16   Max: 0.97
Current: 0.91

0.16
0.97
F-Score: 3
Z-Score: 41.88
M-Score: 2.10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -41261.84
TGTX's Operating margin (%) is ranked lower than
97% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. TGTX: -41261.84 )
TGTX' s 10-Year Operating margin (%) Range
Min: -141552.63   Max: -59
Current: -41261.84

-141552.63
-59
Net-margin (%) -41323.03
TGTX's Net-margin (%) is ranked lower than
96% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -71.50 vs. TGTX: -41323.03 )
TGTX' s 10-Year Net-margin (%) Range
Min: -95121.05   Max: -63.97
Current: -41323.03

-95121.05
-63.97
ROE (%) -87.25
TGTX's ROE (%) is ranked lower than
79% of the 754 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. TGTX: -87.25 )
TGTX' s 10-Year ROE (%) Range
Min: -3919.22   Max: -39.16
Current: -87.25

-3919.22
-39.16
ROA (%) -79.30
TGTX's ROA (%) is ranked lower than
82% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -23.16 vs. TGTX: -79.30 )
TGTX' s 10-Year ROA (%) Range
Min: -543.33   Max: 6.57
Current: -79.3

-543.33
6.57
ROC (Joel Greenblatt) (%) -4979.99
TGTX's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: -344.23 vs. TGTX: -4979.99 )
TGTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -118950   Max: -1066.67
Current: -4979.99

-118950
-1066.67
EBITDA Growth (3Y)(%) 51.80
TGTX's EBITDA Growth (3Y)(%) is ranked higher than
92% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. TGTX: 51.80 )
TGTX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 73
Current: 51.8

0
73
EPS Growth (3Y)(%) 55.00
TGTX's EPS Growth (3Y)(%) is ranked higher than
93% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. TGTX: 55.00 )
TGTX' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 71.4
Current: 55

0
71.4
» TGTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

TGTX Guru Trades in

Q3 2014

TGTX Guru Trades in Q3 2014

Jim Simons 11,199 sh (New)
» More
Q4 2014

TGTX Guru Trades in Q4 2014

Jim Simons 157,881 sh (+1309.78%)
» More
Q1 2015

TGTX Guru Trades in Q1 2015

Jim Simons 19,399 sh (-87.71%)
» More
» Details

Insider Trades

Latest Guru Trades with TGTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.10
TGTX's P/B is ranked lower than
96% of the 713 Companies
in the Global Biotechnology industry.

( Industry Median: 3.32 vs. TGTX: 7.10 )
TGTX' s 10-Year P/B Range
Min: 0   Max: 15.4
Current: 7.1

0
15.4
Current Ratio 12.12
TGTX's Current Ratio is ranked higher than
81% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. TGTX: 12.12 )
TGTX' s 10-Year Current Ratio Range
Min: 0.06   Max: 35.5
Current: 12.12

0.06
35.5
Quick Ratio 12.12
TGTX's Quick Ratio is ranked higher than
81% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 4.07 vs. TGTX: 12.12 )
TGTX' s 10-Year Quick Ratio Range
Min: 0.06   Max: 35.5
Current: 12.12

0.06
35.5
Days Sales Outstanding 216.12
TGTX's Days Sales Outstanding is ranked lower than
89% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. TGTX: 216.12 )
TGTX' s 10-Year Days Sales Outstanding Range
Min: 13.15   Max: 206.51
Current: 216.12

13.15
206.51

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.10
TGTX's Price/Net Cash is ranked lower than
77% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. TGTX: 8.10 )
TGTX' s 10-Year Price/Net Cash Range
Min: 1.18   Max: 620.4
Current: 8.1

1.18
620.4
Price/Net Current Asset Value 8.00
TGTX's Price/Net Current Asset Value is ranked lower than
75% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. TGTX: 8.00 )
TGTX' s 10-Year Price/Net Current Asset Value Range
Min: 1.17   Max: 3515.62
Current: 8

1.17
3515.62
Price/Tangible Book 7.20
TGTX's Price/Tangible Book is ranked lower than
97% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TGTX: 7.20 )
TGTX' s 10-Year Price/Tangible Book Range
Min: 0.65   Max: 5273.43
Current: 7.2

0.65
5273.43
Price/DCF (Projected) 113.90
TGTX's Price/DCF (Projected) is ranked lower than
164% of the 151 Companies
in the Global Biotechnology industry.

( Industry Median: 2.40 vs. TGTX: 113.90 )
TGTX' s 10-Year Price/DCF (Projected) Range
Min: 5.36   Max: 313
Current: 113.9

5.36
313
Earnings Yield (Greenblatt) -8.70
TGTX's Earnings Yield (Greenblatt) is ranked lower than
70% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. TGTX: -8.70 )
TGTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -11.6   Max: 1470.1
Current: -8.7

-11.6
1470.1

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:NKB2.Germany,
TG Therapeutics Inc, was incorporated in Delaware in 1993. The Company is a biopharmaceutical company focused on the acquisition, development, and commercialization of new and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the Company is developing two advanced therapies targeting hematological malignancies. TGTX-1101 or ublituximab which is a novel, third generation monoclonal antibody that targets a specific and single epitope on the CD20 antigen found on mature B-lymphocytes, currently in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The Company is also developing TGR-1202, an orally available PI3K delta inhibitor. The phosphoinositide-3-kinases or PI3Ks are a family of enzymes involved in cellular functions, including cell proliferation and survival, cell differentiation, intracellular trafficking and immunity. There are four isoforms of PI3K: alpha, beta, delta, and gamma, of which the delta isoform is strongly expressed in cells of hematopoietic origin, and often implicated in B-cell related lymphomas. TGR-1202 is being developed jointly with Rhizen Pharmaceuticals, S A. TGR-1202 has demonstrated activity in preclinical xenograft models and primary cells from patients for hematologic cancers. The Company competes with Roche Group, Gazyva, Spectrum Pharmaceutical, Dr. Reddy's Laboratories', among others.
» More Articles for TGTX

Headlines

Articles On GuruFocus.com
Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 
comment on TGTX Mar 09 2013 
comment on TGTX Mar 09 2013 

More From Other Websites
TG THERAPEUTICS, INC. Financials May 20 2015
10-Q for TG Therapeutics, Inc. May 13 2015
TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 51st Annual Meeting of... May 13 2015
TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 51st Annual Meeting of... May 13 2015
TG THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report May 11 2015
TG THERAPEUTICS, INC. Files SEC form 8-K/A, Results of Operations and Financial Condition May 05 2015
10-K for TG Therapeutics, Inc. May 04 2015
TG Therapeutics reports 1Q loss May 04 2015
TG Therapeutics reports 1Q loss May 04 2015
TG THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 04 2015
TG Therapeutics, Inc. Announces First Quarter 2015 Financial Results and Business Update May 04 2015
TG Therapeutics, Inc. Announces First Quarter 2015 Financial Results and Business Update May 04 2015
TG Therapeutics, Inc. to Present at the Deutsche Bank 40th Annual Health Care Conference May 01 2015
TG Therapeutics, Inc. to Present at the Deutsche Bank 40th Annual Health Care Conference May 01 2015
TG Therapeutics, Inc. to Host Conference Call on First Quarter 2015 Financial Results and Business... Apr 30 2015
TG Therapeutics, Inc. to Host Conference Call on First Quarter 2015 Financial Results and Business... Apr 30 2015
Ligand Partner TG Therapeutics Presents Positive Pre-clinical Data on IRAK4 Compounds at the... Apr 20 2015
TG Therapeutics, Inc. Presents Pre-clinical Data on IRAK4 Compounds at the American Association for... Apr 20 2015
TG Therapeutics, Inc. Presents Pre-clinical Data on IRAK4 Compounds at the American Association for... Apr 20 2015
Cramer Remix: This is what I think of Netflix Apr 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK